Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 5812607, 9 pages
https://doi.org/10.1155/2017/5812607
Research Article

Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus

1The Key Laboratory of Pharmacology and Medical Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang 471023, China
2School Clinic, Henan University of Science and Technology, Luoyang 471023, China
3Department of Clinical Research & Development, Hua Medicine, Shanghai 201203, China

Correspondence should be addressed to Shoumin Xi; moc.361@ixnimuohs

Received 29 September 2016; Revised 1 December 2016; Accepted 27 December 2016; Published 16 January 2017

Academic Editor: Konstantinos Kantartzis

Copyright © 2017 Ping Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 29, no. 1, pp. S43–S48, 2006. View at Google Scholar
  2. L. Guariguata, D. R. Whiting, I. Hambleton, J. Beagley, U. Linnenkamp, and J. E. Shaw, “Global estimates of diabetes prevalence for 2013 and projections for 2035,” Diabetes Research and Clinical Practice, vol. 103, no. 2, pp. 137–149, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. D. E. Moller, “Metabolic disease drug discovery—‘hitting the target’ is easier said than done,” Cell Metabolism, vol. 15, no. 1, pp. 19–24, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Al-Hasani, M. H. Tschöp, and S. W. Cushman, “Two birds with one stone: novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism,” Molecular Interventions, vol. 3, no. 7, pp. 367–370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Pal, “Recent advances in glucokinase activators for the treatment of type 2 diabetes,” Drug Discovery Today, vol. 14, no. 15-16, pp. 784–792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. F. M. Matschinsky, “Assessing the potential of glucokinase activators in diabetes therapy,” Nature Reviews Drug Discovery, vol. 8, no. 5, pp. 399–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. F. M. Matschinsky, “Glucokinase, glucose homeostasis, and diabetes mellitus,” Current Diabetes Reports, vol. 5, no. 3, pp. 171–176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Agius, “Glucokinase and molecular aspects of liver glycogen metabolism,” Biochemical Journal, vol. 414, no. 1, pp. 1–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. L. Gloyn, “Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy,” Human Mutation, vol. 22, no. 5, pp. 353–362, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Leighton, A. Atkinson, and M. P. Coghlan, “Small molecule glucokinase activators as novel anti-diabetic agents,” Biochemical Society Transactions, vol. 33, no. 2, pp. 371–374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. R. C. Bonadonna, T. Heise, C. Arbet-Engels et al., “Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: A Mechanistic Study,” Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 11, pp. 5028–5036, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. E. Meininger, R. Scott, M. Alba et al., “Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes,” Diabetes Care, vol. 34, no. 12, pp. 2560–2566, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. F. De Ceuninck, C. Kargar, C. Ilic et al., “Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans,” British Journal of Pharmacology, vol. 168, no. 2, pp. 339–353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. H. Wilding, M. Leonsson-Zachrisson, C. Wessman, and E. Johnsson, “Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin,” Diabetes, Obesity and Metabolism, vol. 15, no. 8, pp. 750–759, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. V. V. Heredia, J. Thomson, D. Nettleton, and S. Sun, “Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis,” Biochemistry, vol. 45, no. 24, pp. 7553–7562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. F. C. Schuit, P. Huypens, H. Heimberg, and D. G. Pipeleers, “Glucose sensing in pancreatic β-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus,” Diabetes, vol. 50, no. 1, pp. 1–11, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Reed, K. Meszaros, L. J. Entes et al., “A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat,” Metabolism, vol. 49, no. 11, pp. 1390–1394, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Zhang, X.-Y. Lv, J. Li, Z.-G. Xu, and L. Chen, “The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model,” Experimental diabetes research, vol. 2008, Article ID 704045, 2008. View at Google Scholar · View at Scopus
  19. M. A. Abdul-Ghani, C. P. Jenkinson, D. K. Richardson, D. Tripathy, and R. A. DeFronzo, “Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the veterans administration genetic epidemiology study,” Diabetes, vol. 55, no. 5, pp. 1430–1435, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Matsuda and R. A. DeFronzo, “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp,” Diabetes Care, vol. 22, no. 9, pp. 1462–1470, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, “Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS),” Circulation, vol. 102, no. 1, pp. 42–47, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-P. Després, B. Lamarche, P. Mauriège et al., “Hyperinsulinemia as an independent risk factor for ischemic heart disease,” New England Journal of Medicine, vol. 334, no. 15, pp. 952–958, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Modan, H. Halkin, S. Almog et al., “Hyperinsulinemia. A link between hypertension obesity and glucose intolerance,” Journal of Clinical Investigation, vol. 75, no. 3, pp. 809–817, 1985. View at Publisher · View at Google Scholar · View at Scopus
  24. J. F. Caro, S. Triester, V. K. Patel, E. B. Tapscott, N. L. Frazier, and G. L. Dohm, “Liver glucokinase: decreased activity in patients with type II diabetes,” Hormone and Metabolic Research, vol. 27, no. 1, pp. 19–22, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Seoane, A. Barberà, S. Télémaque-Potts, C. B. Newgard, and J. J. Guinovart, “Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats,” The Journal of Biological Chemistry, vol. 274, no. 45, pp. 31833–31838, 1999. View at Publisher · View at Google Scholar · View at Scopus